PharmaEngine
Manufacturing · Taiwan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11f No. 10 Sec. 3 Minsheng E. Rd, Taipei...Website
www.pharmaengine.comRevenue
$17.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About PharmaEngine
智擎生技 specializes in cancer treatment, focusing on the development of nanotechnology-based anticancer drugs. Their flagship product, ONIVYDE, is a liposomal formulation of camptothecin used for treating pancreatic cancer patients who have failed standard gemcitabine therapy, and it is available in over 40 countries including Taiwan, the USA, and Europe. Additionally, they are developing a new drug, PEP07, a CHK1 inhibitor currently in Phase I clinical trials. The company aims to provide precise cancer therapies through innovative research in DNA damage response and synthetic lethality.Explore more
PharmaEngine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PharmaEngine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if PharmaEngine had a recent Job posting/layoffs
Earning: See what the market has to say on PharmaEngine recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if PharmaEngine is spiking on competitors!
Funding: Get notified immidiatlly once PharmaEngine has new funding data
Product Launch: Get notified when PharmaEngine launches new products
PharmaEngine, which may be a good buyer, showed buying intent in Masked Content Topic
Check if PharmaEngine has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at PharmaEngine
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined PharmaEngine as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
PharmaEngine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PharmaEngine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PharmaEngine.
PharmaEngine Tech Stack
A closer look at the technologies used by PharmaEngine
PharmaEngine News & Media
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia's Human Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authorityNanobiotix, PharmaEngine Terminate Development Pact For Radiation Therapy In APAC Region
Nanobiotix (NASDAQ: NBTX) and PharmaEngine Inc have read moreNANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (“PharmaEngine”) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012. As previously disclosed iPharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor
TAIPEI, Dec. 4, 2020 /PRNewswire/ -- PharmaEngine, Inc. (TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578, a Checkpoint Kinase 1 (Chk1) inhibitor, under which...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding PharmaEngine
Sign Up For FreeTo access detailed company insights
智擎生技 specializes in cancer treatment, focusing on the development of nanotechnology-based anticancer drugs. Their flagship product, ONIVYDE, is a liposomal formulation of camptothecin used for treating pancreatic cancer patients who have failed standard gemcitabine therapy, and it is available in over 40 countries including Taiwan, the USA, and Eur... Read More
